6.2. medical treatment. patients receiving α1-blockers, muscarinic receptor antagonists, beta-3 agonists, pde5is combination α1-blockers 5-aris muscarinic receptor antagonists reviewed four six weeks drug initiation determine treatment response. patients gain symptomatic relief absence troublesome adverse events, drug therapy may continued. patients reviewed six months annually, provided deterioration symptoms development absolute indications surgical treatment. following recommended follow-up visits: history, ipss/iciq-mluts, uroflowmetry, pvr volume. frequency volume charts bladder diaries used assess response treatment predominant storage symptoms nocturnal polyuria. patients receiving 5-aris reviewed twelve weeks six months determine response adverse events. following recommended follow-up visits: history, ipss/iciq-mluts, uroflowmetry pvr volume. men taking 5-aris followed regularly using serial psa testing life expectancy greater ten years diagnosis pca could alter management. new baseline psa determined six months, confirmed increase psa 5-aris evaluated. patients receiving desmopressin, serum sodium concentration measured day three seven, one month initiating therapy periodically treatment. serum sodium concentration remained normal periodic screening follow-up screening carried every three months subsequently. however, serum sodium concentration monitored frequently patients ≥ 65 years age patients increased risk hyponatremia. following tests recommended follow-up visits: serum-sodium concentration fvc. follow-up sequence restarted dose escalation.